Literature DB >> 31787821

Is Anticoagulant Necessary in Patients with Coronary Artery Ectasia Presenting with Acute Coronary Syndrome? A Systematic Review of Case Reports.

Raymond Pranata1, Emir Yonas2, Veresa Chintya3, Amir Aziz Alkatiri4.   

Abstract

Coronary artery ectasia is found in 3 to 8% of patient's undergoing angiography and may sometimes induce acute myocardial infarction. Some articles reported a recurrence of acute coronary syndrome (ACS) in the presence of coronary artery ectasia (CAE). Our study aims to summarize the latest evidence on whether the use of anticoagulant in addition to SAPT/DAPT (single antiplatelet/dual antiplatelet) treating ACS with CAE patients is necessary. Since the trials concerning our objectives were scarce, we pooled case reports/series. We performed a comprehensive search on case reports/series on coronary artery ectasia that presented with acute coronary syndrome published until March 2019. We collected 13 cases from 11 reports. Out of 13 patients, 5 (38.5%) took DAPT only without anticoagulant and 8 (61.5%) took anticoagulant ± DAPT. Three out of five (60%) who took DAPT only, experienced recurrences at 1st and 2nd months' follow-up. The other two (40%) was uneventful at a mean of two months' follow-up. Eight patients who took anticoagulant were uneventful for a mean of 8.4 months. Those who took anticoagulant were at lower risk of experiencing ACS recurrence ( p  = 0.035). Two of the patients who experienced recurrence became 6 and 12 months free after optimal anticoagulation. The author of this study proposed that anticoagulant must be considered should SAPT/DAPT failed to provide adequate protection to the recurrence of ACS, especially in CAE patients who did not have other obvious stenotic lesions. However, the evidence is weak since this study only pooled case reports/series. © Thieme Medical Publishers.

Entities:  

Keywords:  acute coronary syndrome; anticoagulant; antiplatelet; antithrombotic; coronary artery ectasia; recurrence; triple therapy

Year:  2019        PMID: 31787821      PMCID: PMC6882670          DOI: 10.1055/s-0039-1692706

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  22 in total

1.  Documentation of slow coronary flow by the TIMI frame count in patients with coronary ectasia.

Authors:  M C Papadakis; A Manginas; P Cotileas; V Demopoulos; V Voudris; G Pavlides; S G Foussas; D V Cokkinos
Journal:  Am J Cardiol       Date:  2001-11-01       Impact factor: 2.778

2.  Staged interventional management of a massive thrombus related to coronary artery ectasia in acute coronary syndrome.

Authors:  Makoto Furugen; Yoshitoki Takagawa
Journal:  Cardiovasc Interv Ther       Date:  2011-11-11

3.  Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.

Authors:  Tomoya Hara; Daiju Fukuda; Kimie Tanaka; Yasutomi Higashikuni; Yoichiro Hirata; Sachiko Nishimoto; Shusuke Yagi; Hirotsugu Yamada; Takeshi Soeki; Tetsuzo Wakatsuki; Michio Shimabukuro; Masataka Sata
Journal:  Atherosclerosis       Date:  2015-03-19       Impact factor: 5.162

Review 4.  Nonsurgical management of left main coronary artery aneurysms: report of 2 cases and review of the literature.

Authors:  Brian Lima; Shalendra K Varma; James E Lowe
Journal:  Tex Heart Inst J       Date:  2006

5.  Outcome of primary percutaneous intervention in patients with infarct-related coronary artery ectasia.

Authors:  Ismail Erden; Emine Cakcak Erden; Hakan Ozhan; Ahmet Karabulut; Serkan Ordu; Mehmet Yazici
Journal:  Angiology       Date:  2010-04-14       Impact factor: 3.619

6.  Aneurysmal dilatation of the coronary arteries: diagnostic patterns and clinical significance.

Authors:  S S al-Harthi; M S Nouh; M Arafa; M al-Nozha
Journal:  Int J Cardiol       Date:  1991-02       Impact factor: 4.164

7.  Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells.

Authors:  Jian Liu; Galina K Sukhova; Jin-Tian Yang; Jiusong Sun; Likun Ma; An Ren; Wei-Hua Xu; Huanxiang Fu; Gregory M Dolganov; Chengcheng Hu; Peter Libby; Guo-Ping Shi
Journal:  Atherosclerosis       Date:  2005-06-27       Impact factor: 5.162

8.  Coronary artery ectasia. Its prevalence and clinical significance in 4993 patients.

Authors:  G G Hartnell; B M Parnell; R B Pridie
Journal:  Br Heart J       Date:  1985-10

9.  Novel Direct Anticoagulants and Atherosclerosis.

Authors:  Andrej Fabjan; Fajko F Bajrović
Journal:  Curr Vasc Pharmacol       Date:  2019       Impact factor: 2.719

10.  Thrombosis and anticoagulation therapy in coronary ectasia.

Authors:  P E Perlman; N A Ridgeway
Journal:  Clin Cardiol       Date:  1989-09       Impact factor: 2.882

View more
  4 in total

1.  Dual Antiplatelet Therapy Versus Antiplatelet Monotherapy Plus Oral Anticoagulation in Patients with Acute Coronary Syndrome and Coronary Artery Ectasia: Design and Rationale of OVER-TIME Randomized Clinical Trial.

Authors:  Diego Araiza-Garaygordobil; Rodrigo Gopar-Nieto; Daniel Sierra-Lara Martínez; Nallely Belderrain-Morales; Vianney Sarabia-Chao; Diana Laura Alfaro-Ponce; Heriberto Ontiveros-Mercado; Salvador Mendoza-García; Alfredo Altamirano-Castillo; Pablo Martinez-Amezcua; Alejandro Cabello-López; Jose Luis Briseño-De la Cruz; Maximiliano Ruiz-Beltrán; Marco Antonio Martínez-Ríos; Yigal Piña-Reyna; Hector Gonzalez-Pacheco; Alexandra Arias-Mendoza
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-07-29

2.  Antithrombotic treatment strategy for patients with coronary artery ectasia and acute myocardial infarction: A case report.

Authors:  Rui-Feng Liu; Xiang-Yu Gao; Si-Wen Liang; Hui-Qiang Zhao
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

3.  Is Coronary Artery Ectasia a Progressive Disease? A Self-Controlled Retrospective Cohort Study.

Authors:  Ruifeng Liu; Huiqiang Zhao; Xiangyu Gao; Siwen Liang
Journal:  Front Cardiovasc Med       Date:  2021-12-06

4.  Anti-inflammatory effects of rosuvastatin treatment on coronary artery ectasia patients of different age groups.

Authors:  Cheng-Hui Fan; Ying Hao; Yong-Hua Liu; Xiao-Lin Li; Zhen-Hao Huang; Yu Luo; Rui-Lin Li
Journal:  BMC Cardiovasc Disord       Date:  2020-07-11       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.